| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Wnt/β-catenin signalling, inhibitor (IC50 = 4.1 nM); β-catenin degradation; Axin1 stabilisation.
|
|---|---|
| ln Vitro |
YW-1128 inhibits Wnt/β-catenin reporter activity with an IC50 of 4.1 nM, demonstrating sub-nanomolar potency. It reduces β-catenin protein levels in the presence of lithium chloride (a GSK3β inhibitor) and increases Axin1 levels in HEK293 cells, suggesting a mechanism involving β-catenin degradation complex stabilization.
|
| ln Vivo |
In vivo, YW-1128 is orally active and has potential for treating metabolic disorders, with anti-obesity applications. Systemic dosing (e.g., 1–30 mg/kg/day, oral) would be expected to inhibit Wnt/β-catenin signalling in target tissues and modulate metabolic parameters.
|
| Enzyme Assay |
No specific cell-free enzyme or receptor binding assay is reported. Its activity is defined by cellular Wnt/β-catenin reporter assays, and target engagement is inferred from reduced β-catenin and increased Axin1 protein levels.
|
| Cell Assay |
For cell-based assays, HEK293 or Wnt-responsive cancer cells are treated with YW-1128 (0.1 nM–10 μM) for 12–24 h. Wnt reporter activity is measured by luciferase assay, and β-catenin and Axin1 protein levels by Western blot.
|
| Animal Protocol |
For in vivo studies, obese or metabolic disorder models receive YW-1128 (e.g., 1–30 mg/kg/day, oral) for 2–8 weeks, and body weight, glucose tolerance and tissue Wnt target gene expression are measured.
|
| References |
| Molecular Formula |
C20H17N5O
|
|---|---|
| Molecular Weight |
343.381883382797
|
| Exact Mass |
343.143
|
| CAS # |
2131223-64-6
|
| PubChem CID |
137375558
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Index of Refraction |
1.687
|
| LogP |
3.13
|
| tPSA |
72.7
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
26
|
| Complexity |
501
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC=CC=C1N2C(=C(N=N2)C(=O)NC3=NC4=CC=CC=C4C=C3)C
|
| InChi Key |
SXZFICNOPPNYJM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H17N5O/c1-13-7-3-6-10-17(13)25-14(2)19(23-24-25)20(26)22-18-12-11-15-8-4-5-9-16(15)21-18/h3-12H,1-2H3,(H,21,22,26)
|
| Chemical Name |
5-methyl-1-(2-methylphenyl)-N-quinolin-2-yltriazole-4-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~291.2 mM; with ultrasonication and warming by heating to 160°C)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (7.28 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution; with ultrasonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9122 mL | 14.5611 mL | 29.1223 mL | |
| 5 mM | 0.5824 mL | 2.9122 mL | 5.8245 mL | |
| 10 mM | 0.2912 mL | 1.4561 mL | 2.9122 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.